Results 121 to 130 of about 27,503 (257)

Insulin-reducing effect of adding imeglimin to ongoing dipeptidyl peptidase-4 inhibitor therapy with multiple daily insulin injections (INSPIRE study). [PDF]

J Diabetes Investig
Itsukaichi A, Yoshikawa F, Saito M, Fuchigami A, Iwata Y, Sato G, Uchino H, Hirose T.   +7 more
europepmc   +1 more source

Diabetes attenuates weight reduction‐mediated liver fibrosis regression in persons with morbid obesity

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Weight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low‐calorie diet: LCD) ameliorates diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1‐year after LSG and their associations with metabolic factors in Japanese participants with
Daiki Matsubara, Yumie Takeshita, Masahiro Mori, Yujiro Nakano, Kenichi Harada, Noboru Takata, Kengo Hayashi, Hideki Moriyama, Noriyuki Inaki, Masao Honda, Taro Yamashita, Toshinari Takamura   +11 more
wiley   +1 more source

Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis. [PDF]

Korean Circ J, 2023
Kim KJ, Park JB, Lee SP, Kim HK, Kim YJ.
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

Journal of the American College of Cardiology, 2012
openaire   +1 more source

Epigenomic Cascades Across Organs in Metabolic Dysfunction–Associated Steatotic Liver Disease: New Therapeutic Horizons

Obesity Reviews, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide, affecting approximately one‐third of the population and increasing the risk of severe hepatic and cardiovascular complications.
Shurui Yang, Zhongyu Huang, Sanchun Tan, Fengxia Liang, Li Chen   +4 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. [PDF]

Cureus
Roa Alvarez G, Shuchleib Cukiert M, Hernández Altamirano FR, Berumen Glinz C, Vega Memije ME.   +4 more
europepmc   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

Obesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra, Sara G. I. Suliman, Mohammed Al‐Hadad, Dorret I. Boomsma, Fadwa Alhantoobi, Maithah Alsamahi, Haneen Abufarajallah, Alia Al Tikriti, Zeyar Aung, Selena Richards, Abdulrahim Sajini, Mira Mousa, Fatima Sulaiman, Wael Osman   +13 more
wiley   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. [PDF]

Drugs Real World Outcomes
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai, Gil Caspi, Akhilanand Chaurasia, Gavriel Chaushu, Daya Masri, Ehud Jonas   +5 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients with COPD and Diabetes: A Nationwide Retrospective Cohort Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Ho CH, Shao YC, Wu YC, Liao KM.
europepmc   +1 more source